Docoh
Loading...
Sign up Log in

BMRA Biomerica

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.

Company profile

Ticker
BMRA
Exchange
NASDAQ
Website
www.biomerica.com
CEO
Zackary S. Irani
Employees
Incorporated
Delaware
Location
California
Fiscal year end
May 31
Sector
Manufacturing > Dental Equipment and Supplies Manufacturing
Industry (SIC)
In Vitro & In Vivo Diagnostic Substances
Ortho Clinical Diagnostics • Idexx Laboratories • Myriad Genetics • Quidel • Lantheus • Neogen • Meridian Bioscience • Celldex Therapeutics • Oxford Immunotec Global • Lucira Health ...
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
0000073290
Corporate docs
IRS number
952645573

BMRA stock data

(
)

News

Pro users get this 30m faster
Biomerica Signs Exclusive Distribution Agreement In Canada For Helicobacter Pylori (H. pylori) Test, hp+detect
24 Jun 21
Biomerica Inc. (NASDAQ:BMRA) today announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomerica's new and
Biomerica Receives Notice Of Allowance From Mexican Patent Office For Irritable Bowel Syndrome Food Sensitivity Testing & Treatment
15 Jun 21
Biomerica, Inc. (NASDAQ:BMRA) today announced that the Mexican Patent Office has issued a notice of allowance for Biomerica's patent application pertaining to the Company's InFoods® technology platform
64 Biggest Movers From Friday
14 Jun 21
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share.
46 Stocks Moving In Friday's Mid-Day Session
11 Jun 21
12 Health Care Stocks Moving In Friday's Intraday Session
11 Jun 21

Press releases

Pro users get this 30m faster
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™
24 Jun 21
Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA) today announced that it has signed an
Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment
15 Jun 21
IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% [1] (approximately 20 million patients)Broadens InFoods® global patent coverage with recently allowed patents in
Thinking about buying stock in AMC Entertainment, Comstock Mining, Onconova Therapeutics, Palantir Technologies, or Biomerica?
19 May 21
NEW YORK, May 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, LODE, ONTX, PLTR, and BMRA.
Thinking about buying stock in Minerva Neurosciences, Fubotv, Lucira Health, Biomerica, or Comstock Mining?
12 May 21
Biomerica's Fast 15-Minute Easy to Use COVID-19 Antigen Test Now Available With Simple Nasal Swab
11 May 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 Apr 21
28 Jul 21
31 May 22

Financial summary

Financial statements Chart BMRA financial data
Quarter (USD)
 Feb 21 Nov 20 Aug 20 May 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 May 20 May 19 May 18 May 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Biomerica earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.27M 5.27M 5.27M 5.27M 5.27M 5.27M
Cash burn (monthly) 137.07K (positive/no burn) 626.7K 458.68K 454.62K 644.89K
Cash used (since last report) 686.75K n/a 3.14M 2.3M 2.28M 3.23M
Cash remaining 4.59M n/a 2.13M 2.97M 2.99M 2.04M
Runway (months of cash) 33.5 n/a 3.4 6.5 6.6 3.2

Beta Read what these cash burn values mean

Recent insider trades

BMRA insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 Mar 21 Barbieri Allen Common Stock Gift Dispose G No No 0 22,500 0 114,789
26 Mar 21 Barbieri Allen Common Stock Gift Dispose G No No 0 22,500 0 114,789
10 Dec 20 Zackary S. Irani NQSO Common Stock Grant Aquire A No No 6.36 78,616 500K 633,616
10 Dec 20 Steven Sloan NQSO Common Stock Grant Aquire A No No 6.36 25,000 159K 75,000
10 Dec 20 Barbieri Allen NQSO Common Stock Grant Aquire A No No 6.36 30,000 190.8K 220,000
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

BMRA institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

43.3% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 35 31 +12.9%
Opened positions 8 8 –
Closed positions 4 3 +33.3%
Increased positions 9 11 -18.2%
Reduced positions 8 7 +14.3%
13F shares
 Current Prev Q Change
Total value 28.33M 29.8M -4.9%
Total shares 5.33M 4.58M +16.3%
Total puts 50.9K 55.1K -7.6%
Total calls 67.6K 0 NEW
Total put/call ratio 0.8 Infinity NaN%
Largest owners
 Shares Value Change
Wellington Management 973.7K $5.32M +12.4%
WELLINGTON TRUST Co N A 866K $4.31M 0.0%
Granahan Investment Management 830.06K $4.53M +62.5%
Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio 723.2K $3.6M 0.0%
Vanguard 600.63K $3.28M +5.8%
Russell Investments 285.35K $1.56M -27.5%
Millrace Asset 247.71K $1.35M +243.7%
BLK Blackrock 220.36K $1.2M +4.9%
Marshall Wace 165.24K $902K NEW
Fore Capital 77.14K $421K NEW
Largest transactions
 Shares Bought/sold Change
Granahan Investment Management 830.06K +319.14K +62.5%
Millrace Asset 247.71K +175.63K +243.7%
Marshall Wace 165.24K +165.24K NEW
Russell Investments 285.35K -108.05K -27.5%
Wellington Management 973.7K +107.7K +12.4%
Fore Capital 77.14K +77.14K NEW
Vanguard 600.63K +32.93K +5.8%
Squarepoint Ops 0 -26.85K EXIT
BCS Barclays 72 -23.93K -99.7%
GWM Advisors 22.3K +22.3K NEW
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Management Discussion
  • Our consolidated net sales were $6,692,711 for fiscal 2020 compared to $5,200,682 for fiscal 2019. This represents an increase of $1,492,029, or 28.7%. This increase in annual sales is primarily attributable to sales of COVID-19 tests during the last quarter of the fiscal year, which offset decreases in other product lines that were negatively impacted by the COVID-19 pandemic and related national and international mandates affecting consumers. Our consolidated net sales were $2,725,000 for the fiscal fourth quarter 2020, compared to $1,165,860 for fiscal fourth quarter of 2019.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: American, called, choose, compliance, Concurrently, default, downturn, EZ, failed, fell, hundred, internationally, launch, launched, longer, Moderna, moving, NASDAQ, ownership, percent, Pfizer, protein, readily, RNA, shifted, spike, typically, website
Removed: ASU, finger, higher, institution, prick, promising, similar, standard
From filing 10-Q 2021 Q3

Financial reports

View all
10-Q
2021 Q3
Quarterly report
14 Apr 21
10-Q
2021 Q2
Quarterly report
14 Jan 21
10-Q
2021 Q1
Quarterly report
15 Oct 20
10-K
2020 FY
Annual report
31 Aug 20
10-Q
2020 Q3
Quarterly report
14 Apr 20
10-Q
2020 Q2
Quarterly report
14 Jan 20
10-Q
2020 Q1
Quarterly report
15 Oct 19
10-K
2019 FY
Annual report
29 Aug 19
10-Q
2019 Q3
Quarterly report
15 Apr 19
10-Q
2019 Q2
Quarterly report
14 Jan 19

Current reports

View all
8-K
Regulation FD Disclosure
24 Jun 21
8-K
Other Events
22 Jan 21
8-K
Biomerica’S Fast 15-Minute Simple to use COVID-19 Antigen RAPID test receives CE Mark
13 Jan 21
8-K
Submission of Matters to a Vote of Security Holders
11 Dec 20
8-K
Departure of Directors or Certain Officers
11 Dec 20
8-K
Regulation FD Disclosure
1 Sep 20
8-K
Departure of Directors or Certain Officers
1 Sep 20
8-K
Regulation FD Disclosure
28 Jun 20
8-K
Regulation FD Disclosure
16 Jun 20
8-K
Regulation FD Disclosure
1 Jun 20

Registration and prospectus

View all
S-8
Registration of securities for employees
21 May 21
424B5
Prospectus supplement for primary offering
22 Jan 21
S-3/A
Shelf registration (amended)
11 Sep 20
S-3
Shelf registration
21 Jul 20
424B5
Prospectus supplement for primary offering
20 Mar 20
D
$2M in equity, sold $2M, 1 investor
27 Feb 20
S-8
Registration of securities for employees
10 May 18
424B5
Prospectus supplement for primary offering
3 Dec 17
S-3
Shelf registration
29 Jun 17
8-A12B
Registration of securities on exchange
22 Aug 16

Proxies

View all
DEF 14A
Definitive proxy
25 Sep 20
DEF 14A
Definitive proxy
24 Sep 19
DEF 14A
Definitive proxy
27 Sep 18
DEF 14A
Definitive proxy
27 Sep 17
DEF 14A
Definitive proxy
27 Sep 16
DEF 14A
Definitive proxy
27 Sep 15
DEF 14A
Definitive proxy
28 Sep 14
DEF 14A
Definitive proxy
29 Sep 13
DEF 14A
Definitive proxy
27 Sep 12
DEF 14A
Definitive proxy
27 Sep 11

Other

View all
EFFECT
Notice of effectiveness
1 Oct 20
CORRESP
Correspondence with SEC
27 Sep 20
CORRESP
Correspondence with SEC
10 Sep 20
CORRESP
Correspondence with SEC
8 Sep 20
UPLOAD
Letter from SEC
27 Jul 20
EFFECT
Notice of effectiveness
19 Jul 17
CORRESP
Correspondence with SEC
17 Jul 17
UPLOAD
Letter from SEC
5 Jul 17
UPLOAD
Letter from SEC
16 Mar 09
CORRESP
Correspondence with SEC
15 Mar 09

Ownership

View all
5/A
BIOMERICA / ALLEN BARBIERI ownership change
28 Jun 21
5
BIOMERICA / ALLEN BARBIERI ownership change
25 Jun 21
SC 13G
BIOMERICA / WELLINGTON MANAGEMENT ownership change
3 Feb 21
SC 13G/A
BIOMERICA / Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio ownership change
3 Feb 21
SC 13G
BIOMERICA / WELLINGTON TRUST Co N A ownership change
3 Feb 21
SC 13G/A
BIOMERICA / Intelligent Fanatics Capital Management ownership change
20 Jan 21
4
BIOMERICA / FRANCIS CANO ownership change
11 Dec 20
4
BIOMERICA / Jane Emerson ownership change
11 Dec 20
4
BIOMERICA / Catherine Coste ownership change
11 Dec 20
4
BIOMERICA / Mark A Sirgo ownership change
11 Dec 20

Patents

APP
Utility
Compositions, Devices, and Methods of Ibs Sensitivity Testing
10 Jun 21
Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value.
GRANT
Utility
IBS sensitivity testing
28 Sep 20
Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value.
APP
Utility
Compositions, Devices, and Methods of Attention Deficit Disorder/attention Deficit Hyperactivity Disorder (Add/adhd) Sensitivity Testing
1 Jan 20
Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value.

Reddit threads

Pro users get this 30m faster